Allogene Therapeutics Inc (NAS:ALLO)
$ 2.095 0.015 (0.72%) Market Cap: 437.40 Mil Enterprise Value: 138.33 Mil PE Ratio: 0 PB Ratio: 0.77 GF Score: 28/100

Allogene Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 08:20PM GMT
Release Date Price: $4.99 (-12.54%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good afternoon, everyone. Thanks so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the Allogene team here with us. So we have David Chang, President, CEO and Co-Founder as well as Eric Schmidt, CFO. And maybe to start here, Eric, given the news today, maybe I just want to walk through just provide us some of your thoughts.

Eric Thomas Schmidt
Allogene Therapeutics, Inc. - Executive VP & CFO

As you're referring to -- so Salveen, as you know, I -- we at Allogene announced my resignation today from the company, and that was with very mixed feelings as you can imagine, I've been an Allogene for 5 years, and I've had the pleasure of working with David and Ari and Christine and many others to create what I really think is a preeminent cell therapy company.

And -- in doing so, out of joy, I've been traveling back and forth, East Coast, West Coast and doing so very regularly. And of course, with that travel,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot